|
In € millions, except earnings per share and dividend (in €) |
2014 | 2015
|
2016 |
2017 | 2018 |
|---|---|---|---|---|---|
|
Order intake |
14,363 | 18,880 | 16,514 | 14,920 | 16,034 |
|
Order book at end of period |
27,885 | 32,292 | 33,530 | 31,914 |
32,329 |
Sales |
12,974 |
14,063 |
14,885 |
15,795 |
15,855 |
| Total change | + 2.2% | + 8.4% | + 5.8% | + 6.1% |
+4.1% |
| Organic change | - 1.2% | + 4.5% | + 6.8% | + 7.2% | +5.3% |
EBIT (1) |
985 |
1,216 |
1,354 |
1,543 | 1,685 |
| In % of sales | 7.6% | 8.6% | 9.1% | 9.8% | 10.6% |
Adjusted net income , Group share (1) |
562 |
809 |
897 |
982 | 1,178 |
Consolidated net income, Group share |
714 | 765 | 946 | 822 | 982 |
Adjusted net income Group share, per share (EPS)(1) |
2.75 |
3.89 |
4.25 |
4.64 | 5.55 |
Dividend per share |
1.12 | 1.36 | 1.60 | 1.75 | 2.08(3) |
Free operating cash-flow (1) |
501 |
1,110 |
954 |
1,365 | 811 |
Net cash position at end of period |
1,006 | 1,978 | 2,366 | 2,971 | 3,181 |
Self-funded R&D(2) |
675 | 707 |
743
|
813 | 879 |
Consolidated headcount at year-end |
61,709 | 62,194 | 64,071 | 64,860 | 66,135 |
- (1) Non-strictly accounting measures. See definitions in the corresponding reference documents.
- (2) Including capitalized R&D
- (3) Proposed to the 15 May 2019 AGM
Contact
Investors relations
+33 (0) 1 57 77 89 02
ir@thalesgroup.com